Stock ALVO ALVOTECH
Add to a list
To use this feature you must be a member
Log inSign up

News Alvotech Nyse

Equities

ALVO

LU2458332611

Real-time Estimate Cboe BZX
Other stock markets
 10:46:29 2024-04-29 am EDT 		5-day change 1st Jan Change
14.32 USD +1.20% Intraday chart for Alvotech +7.03% +52.19%
Apr. 25 Cigna to offer Humira rivals with $0 copay at specialty pharmacy RE
Apr. 24 Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar
AQ
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
RE
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi
AQ
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study
MT
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
GL
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi
CI
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira
AQ
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care Stocks Rise Friday Afternoon
MT
Sector Update: Health Care
MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
MT
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
GL
Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-Concentration Interchangeable Biosimilar to Humira®
CI
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)
CI
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis
MT
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
AQ
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
GL
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment
DJ
J&J beats first-quarter profit estimates on cancer drugs strength
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. ALVO Stock
  5. News Alvotech